In a targeted multi-gene assay analysis [72], among 795 exocrine PC, 73 patients had KRAS-WT tumors (9.2%), 43.8% (32/73) of which had MAPK pathway alterations. This evidence concerns the gene KRAS and pachyonychia congenita.